| # | Drug | Count |
|---|---|---|
| 0 | DUPILUMAB | 16495 |
| 1 | MEPOLIZUMAB | 1614 |
| 2 | BELIMUMAB | 1029 |
| 3 | INSULIN GLARGINE | 943 |
| 4 | SOMATROPIN | 798 |
| 5 | EVOLOCUMAB | 756 |
| 6 | ALBUTEROL SULFATE | 591 |
| 7 | ERGOCALCIFEROL | 366 |
| 8 | ADALIMUMAB-AATY | 298 |
| 9 | PREDNISONE | 295 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | USTEKINUMAB-STBA | 24 | 0.0647 |
| 1 | PERFLUOROHEXYLOCTANE | 133 | 0.0572 |
| 2 | INSULIN GLARGINE AND LIXISENATIDE | 203 | 0.0555 |
| 3 | INFLIXIMAB-DYYB | 141 | 0.0409 |
| 4 | CLINDAMYCIN PHOSPHATE/BENZOYL PEROXIDE/ADAPALENE | 2 | 0.0333 |
| 5 | BELIMUMAB | 1029 | 0.0321 |
| 6 | MEPOLIZUMAB | 1614 | 0.0320 |
| 7 | DUPILUMAB | 16495 | 0.0318 |
| 8 | BACITRACIN ZINC AND NEOMYCIN AND POLYMYXIN B SULFATE | 2 | 0.0282 |
| 9 | BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B, PRAMOXINE HCL | 2 | 0.0278 |
| # | Drug class | Count |
|---|---|---|
| 0 | Interleukin-4 Receptor alpha Antagonist [EPC] | 16495 |
| 1 | Interleukin-5 Antagonist [EPC] | 1615 |
| 2 | Insulin Analog [EPC] | 1211 |
| 3 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 1029 |
| 4 | PCSK9 Inhibitor [EPC] | 820 |
| 5 | Corticosteroid [EPC] | 699 |
| 6 | Tumor Necrosis Factor Blocker [EPC] | 687 |
| 7 | Nonsteroidal Anti-inflammatory Drug [EPC] | 508 |
| 8 | GLP-1 Receptor Agonist [EPC] | 429 |
| 9 | Provitamin D2 Compound [EPC] | 366 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Interleukin-5 Antagonist [EPC] | 1615 | 2.3474 |
| 1 | Semifluorinated Alkane [EPC] | 133 | 0.0572 |
| 2 | B Lymphocyte Stimulator-specific Inhibitor [EPC] | 1029 | 0.0321 |
| 3 | PCSK9 Inhibitor [EPC] | 820 | 0.0318 |
| 4 | Interleukin-4 Receptor alpha Antagonist [EPC] | 16495 | 0.0318 |
| 5 | Polymyxin-class Antibacterial [EPC] | 2 | 0.0274 |
| 6 | Ectoparasiticide [EPC] | 96 | 0.0245 |
| 7 | Antithrombin-directed RNA Interaction [EPC] | 1 | 0.0179 |
| 8 | Guanylate Cyclase-C Agonist [EPC] | 37 | 0.0178 |
| 9 | Oxaborole Antifungal [EPC] | 1 | 0.0143 |